Sheryl A Flanagan
Overview
Explore the profile of Sheryl A Flanagan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao K, Zhang Q, Flanagan S, Lang X, Jiang L, Parsels L, et al.
Mol Cancer Res
. 2021 May;
19(9):1571-1582.
PMID: 34045311
Programmed death-ligand 1 (PD-L1) promotes tumor immune evasion by engaging the PD-1 receptor and inhibiting T-cell activity. While the regulation of PD-L1 expression is not fully understood, its expression is...
2.
Parsels L, Engelke C, Parsels J, Flanagan S, Zhang Q, Tanska D, et al.
Mol Cancer Ther
. 2020 Dec;
20(2):263-273.
PMID: 33268569
PARP inhibitor monotherapy (olaparib) was recently FDA approved for the treatment of BRCA1/2-mutant, homologous recombination (HR) repair-deficient pancreatic cancer. Most pancreatic cancers, however, are HR proficient and thus resistant to...
3.
Ahmad M, Alam I, Huff S, Pink J, Flanagan S, Shewach D, et al.
Proc Natl Acad Sci U S A
. 2017 Jul;
114(31):8241-8246.
PMID: 28716944
Human ribonucleotide reductase (hRR) is crucial for DNA replication and maintenance of a balanced dNTP pool, and is an established cancer target. Nucleoside analogs such as gemcitabine diphosphate and clofarabine...
4.
Im M, Flanagan S, Ackroyd J, Knapp B, Kramer A, Shewach D
Radiat Res
. 2016 Oct;
186(5):466-477.
PMID: 27740890
Gemcitabine (dFdCyd) shows broad antitumor activity in solid tumors in chemotherapeutic regimens or when combined with ionizing radiation (radiosensitization). While it is known that mismatches in DNA are necessary for...
5.
Im M, Flanagan S, Ackroyd J, Shewach D
Radiat Res
. 2015 Jan;
183(1):114-23.
PMID: 25564718
Gemcitabine (difluorodeoxycytidine; dFdCyd) is a potent radiosensitizer, noted for its ability to enhance cytotoxicity with radiation at noncytotoxic concentrations in vitro and subchemotherapeutic doses in patients. Radiosensitization in human tumor...
6.
Ladd B, Ackroyd J, Hicks J, Canman C, Flanagan S, Shewach D
DNA Repair (Amst)
. 2013 Nov;
12(12):1114-21.
PMID: 24231389
The nucleoside analog ganciclovir (GCV) elicits cytotoxicity in tumor cells via a novel mechanism in which drug incorporation into DNA produces minimal disruption of replication, but numerous DNA double strand...
7.
Flanagan S, Cooper K, Mannava S, Nikiforov M, Shewach D
Int J Radiat Oncol Biol Phys
. 2012 Aug;
84(5):e613-20.
PMID: 22867891
Purpose: To determine the effect of short hairpin ribonucleic acid (shRNA)-mediated suppression of thymidylate synthase (TS) on cytotoxicity and radiosensitization and the mechanism by which these events occur. Methods And...
8.
OKonek J, Ladd B, Flanagan S, Im M, Boucher P, Thepsourinthone T, et al.
Mutat Res
. 2009 Dec;
684(1-2):1-10.
PMID: 20004674
Nucleoside analogs are efficacious cancer chemotherapeutics due to their incorporation into tumor cell DNA. However, they exhibit vastly different antitumor efficacies, suggesting that incorporation produces divergent effects on DNA replication....
9.
Flanagan S, Krokosky C, Mannava S, Nikiforov M, Shewach D
Mol Pharmacol
. 2008 Jun;
74(3):863-71.
PMID: 18535288
The antitumor drug 5-fluoro-2'-deoxyuridine (FdUrd) also sensitizes tumor cells to ionizing radiation in vitro and in vivo. Although radiosensitization with FdUrd requires dTTP depletion and S-phase arrest, the exact mechanism...
10.
Flanagan S, Gandhi V, Meckling K
Leuk Lymphoma
. 2007 Sep;
48(9):1816-27.
PMID: 17786719
Guanosine initiated apoptosis in NB4 cells in a transport-dependent manner. Apoptosis was partially attributed to an imbalance in nucleosides with some protection upon the addition of pyrimidines. The effect of...